Antibiotic

JH-LPH-28 is a sulfonyl piperazine analog that functions as an inhibitor of UDP-2,3-diacylglucosamine pyrophosphate hydrolase (LpxH). This compound exhibits significant antibiotic activity, demonstrated by a minimum inhibitory concentration (MIC) of 0.83 μg/mL. JH-LPH-28 is a valuable tool for research applications focused on bacterial resistance mechanisms and antibiotic development.

Cefazolin sodium pentahydrate is a first-generation cephalosporin antibiotic that targets bacterial cell wall synthesis. This reagent exhibits broad-spectrum antibacterial activity, making it useful for research involving various bacterial infections. Additionally, cefazolin sodium pentahydrate has been shown to possess anti-inflammatory properties and may contribute to the attenuation of post-operative cognitive dysfunction (POCD) in relevant studies.

WF-3161 is a cyclic tetrapeptide antibiotic derived from the fungus Petriella guttulata, exhibiting significant anti-tumor activity. It effectively inhibits the growth of Trichophyton asteroides with a minimum inhibitory concentration (MIC) of 3 μg/mL. WF-3161 is valuable for research applications focusing on P-388 leukemia and related studies of fungal infections.

Tomaymycin is an antitumor antibiotic that exerts its effects primarily by targeting and inhibiting bacterial protein synthesis. This compound demonstrates significant antimicrobial activity against Gram-positive bacteria, making it a valuable tool in cancer research and infectious disease studies. Its unique mechanism of action offers researchers insights into tumor cell interactions and potential therapeutic applications in oncology.

Teicoplanin A2-5 is an antibiotic that primarily targets Gram-positive bacteria, demonstrating efficacy against both aerobic and anaerobic species. It is widely used in research to study bacterial infections and antibiotic resistance mechanisms. Teicoplanin A2-5 can also be employed in the development of novel therapeutic strategies against resistant strains.

Cefuzonam is an antibiotic that targets bacterial cell wall synthesis, demonstrating potent antibacterial activity against gram-positive bacteria, including Staphylococcus, Streptococcus, and Neisseria gonorrhoeae, with a minimum inhibitory concentration (MIC) ranging from 0.63 to 2 μg/mL. In addition to its antimicrobial properties, Cefuzonam serves as a corrosion inhibitor for mild steel by enhancing the hydrophobicity of the metal surface when exposed to acidic environments. This dual functionality makes it valuable for both clinical applications and materials science research.

Berkeleylactone E is a macrolide antibiotic that targets bacterial protein synthesis. Exhibiting potent antibacterial activity, it has been shown to effectively inhibit the growth of various pathogenic bacteria. This compound is utilized in research applications focused on elucidating antibiotic mechanisms and developing new therapeutic strategies against resistant strains.

Sanfetrinem cilexetil is a prodrug of Sanfetrinem that functions as an orally active antibiotic. It exhibits strong activity against a range of bacterial pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli in models of murine septicemia, as well as against respiratory infections caused by Streptococcus pneumoniae. This compound is valuable for research applications focused on antibiotic efficacy and the study of bacterial infections.

Bostrycin, also known as Rhodosporin, is an antibiotic with a unique red pigment structure that targets and exhibits strong activity against Gram-positive bacteria. Its mechanism involves disrupting bacterial cell wall synthesis, making it a valuable tool for researching bacterial infections and antibiotic resistance. Bostrycin is particularly relevant in studies focusing on the development of novel antibacterial agents.

Tetronasin sodium is a growth-promoting antibiotic primarily targeting Gram-positive bacteria. It exhibits effective antimicrobial activity, making it suitable for studies related to antibiotic resistance and bacterial infection models. This reagent can be administered orally through the animal's food or water supply, aiding in research applications focused on agricultural and veterinary microbiology.

Leucomycin A13 is a macrolide antibiotic that targets bacterial ribosomes, inhibiting protein synthesis. It exhibits significant antibacterial activity against Bacillus subtilis, Staphylococcus aureus, Micrococcus luteus, and Escherichia coli, with minimum inhibitory concentration (MIC) values of 0.16, 0.16, 0.08, and >10 μg/mL, respectively. Its ribosomal binding affinity is characterized by an IC50 value of 1.2 μM, making it a valuable reagent for research into antibiotic mechanisms and resistance.

Albomycin δ2 is a siderophore-antibiotic conjugate that specifically targets bacterial ribosomes, exhibiting potent antibacterial activity with a minimum inhibitory concentration (MIC) of 0.0625 μg/mL against Streptococcus pneumoniae and 0.125 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). This compound is valuable for research focused on bacterial infections, particularly those caused by S. pneumoniae and S. aureus, and offers insights into novel treatment strategies for antibiotic-resistant pathogens.

Annamycin is an anthracycline antibiotic that primarily targets topoisomerase II, leading to the induction of double-strand DNA breaks and subsequent cell death. It demonstrates potent antitumor activity by exerting cytotoxic effects in various cancer models. Notably, Annamycin has shown efficacy in inhibiting the growth of advanced subcutaneous melanoma and squamous cell carcinoma in mice, while also prolonging survival in models of reticulosarcoma and lung cancer metastasis. This compound is valuable for research applications related to melanoma, reticulum cell sarcoma, and both non-small cell and small cell lung cancers.

Bactobolin C is an antibiotic derived from Pseudomonas sp. BMG13A7, exhibiting potent antimicrobial and antitumor properties. It additionally demonstrates the ability to inhibit antibody production and has potential applications in treating autoimmune encephalomyelitis. Despite its therapeutic promise, the associated toxicity may limit its clinical use. Ongoing research focuses on the total synthesis and structural modification of Bactobolin C, particularly the functionalization of hydroxyl groups on the amino acid side chains and backbone to enhance its biological activity and reduce toxicity.

Piperacillin mixture with tazobactam (8:1) is a β-lactam antibiotic and β-lactamase inhibitor combination. This compound exhibits broad-spectrum antibacterial activity against various pathogens, effectively targeting most Gram-positive bacteria as well as Gram-negative aerobic and anaerobic bacteria, including those that produce β-lactamase. It is commonly utilized in research applications for studying bacterial resistance mechanisms and evaluating the efficacy of antibiotic combinations.

Aranciamycin A is an anthracyclic antibiotic derived from the Streptomyces genus. It exhibits significant antibacterial activity against Mycobacterium bovis and Bacillus subtilis, with minimum inhibitory concentration (MIC) values of 30 µM and 7.5 µM, respectively. This compound is suitable for research applications involving the assessment of antibiotic efficacy and the exploration of bacterial resistance mechanisms.

4"-Isovalerylspiramycin III is an antibiotic that primarily targets bacterial protein synthesis. As the main active component of Shengjimycin, it exhibits potent antibacterial activity, making it a valuable tool in microbiological research. Its efficacy in inhibiting bacterial growth allows for applications in investigating antibiotic resistance mechanisms and developing new therapeutic strategies against bacterial infections.

Chrysomycin B is an antibiotic derived from a Streptomyces strain, primarily functioning as a topoisomerase II inhibitor. It exhibits significant biological activity by inducing DNA damage in the A549 human lung adenocarcinoma cell line and effectively suppresses tumor growth in murine models. This compound is useful for research applications focused on cancer therapeutics and mechanisms of antibiotic action.

A-692345 is a naphthyridone antibiotic that targets bacterial cell processes. It demonstrates significant antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of 8 µg/mL. This compound is suitable for use in antimicrobial research and studies aimed at understanding bacterial resistance mechanisms.

Manumycin B is an antibiotic that also demonstrates notable antitumor activity. It functions as an inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 15 mM. This compound is valuable for research in cancer biology and neuropharmacology, providing insights into therapeutic strategies for cancer treatment and neurodegenerative disorders.

Pyridomycin is a selective inhibitor of InhA, an essential enzyme in Mycobacterium tuberculosis, providing a targeted approach in combating this pathogen. As an antibiotic derived from the metabolites of Dactylosporangium fulvum, Pyridomycin exhibits low cytotoxicity while effectively impeding the growth of Mycobacterium tuberculosis. Its application is significant in the study and treatment of bacterial infections, particularly tuberculosis, making it a valuable reagent for research in infectious disease mechanisms and antibiotic development.

Saptomycin D is an antitumor antibiotic that targets various cancer cell lines and exhibits potent cytotoxicity. Isolated from the Streptomyces sp. HP530 strain, Saptomycin D demonstrates robust inhibitory effects against Gram-positive bacteria and limited activity against some Gram-negative bacteria and yeasts. This compound is particularly relevant for research applications in oncology, offering potential insights into tumor suppression mechanisms and treatment development.

Nocardicin A is a beta-lactam antibiotic targeting bacterial cell wall synthesis. It exhibits moderate antibacterial activity against a wide range of Gram-negative bacteria, including Proteus and Pseudomonas, while demonstrating no inhibitory effects on Staphylococcus, Mycobacterium, fungi, and yeast. This compound is useful in research applications focused on bacterial resistance and the mechanisms of antibiotic action.

PKUMDL-LTQ-301 is a HipA toxin inhibitor that disrupts bacterial persistence by targeting the HipA protein in Escherichia coli. This compound has demonstrated significant reduction in bacterial survival rates in both in vitro and in vivo models, making it a valuable tool for antibiotic research. PKUMDL-LTQ-301's efficacy is supported by specific KD and EC50 values, underscoring its potential in studies focused on overcoming antibiotic resistance and developing novel antibacterial therapies.

Pacidamycin I is a nucleoside peptide antibiotic that selectively targets Pseudomonas aeruginosa. It exhibits potent antibacterial activity, making it a valuable tool for research focused on combating antibiotic-resistant infections. Pacidamycin I is particularly useful in studies of microbial physiology and antibiotic development pathways.

Lavanducyanin is an antibiotic that targets microbial cell membranes, disrupting their integrity and functionality. This compound demonstrates significant antimicrobial activity, making it a valuable tool in the study of infections. Additionally, its potential as an adjuvant in cancer research presents opportunities for further exploration in therapeutic applications.

Celastramycin A is an antibiotic derived from Streptomyces MaB-QuH-8, known for its significant antimicrobial activity against a variety of gram-negative bacteria and mycobacteria, with minimum inhibitory concentrations (MICs) ranging from 0.05 to 3.1 μg/ml. This compound exhibits immunosuppressive effects, evidenced by its ability to modulate immune responses in ex vivo Drosophila and human models, demonstrating an IC50 of 0.008 μg/ml through the immune deficiency pathway and inhibiting TNF-α signaling. Additionally, Celastramycin A effectively reduces IL-8 production in human umbilical vein endothelial cells (HUEVCs), with an IC50 of 0.06 μg/ml, making it a valuable tool for research in microbial resistance and immune modulation.

Fumaramidmycin is an antibiotic derived from Streptomyces kurssanovii NR-7GG1, primarily targeting bacterial cell processes. It exhibits significant antimicrobial activity against a broad spectrum of both Gram-positive and Gram-negative bacteria. This compound is valuable for research applications focused on the mechanisms of antibiotic resistance and the development of novel antimicrobial therapies.

CK0492B is a novel biaminourea antibiotic that targets bacterial plaque formation. Demonstrating significant antiplaque properties in vitro, it has also shown efficacy in reducing dental disease symptoms in an experimental mouse model. A 12-week study conducted in beagles highlighted its effectiveness in decreasing plaque and gingivitis while assessing its safety profile. The selection of canine subjects is informed by the similarities in periodontal disease onset and progression between dogs and humans, with chlorhexidine acetate serving as a positive control for comparison.

1-Hydroxyauramycin B is an anthracycline antibiotic with a primary mechanism of action as an antitumor agent. It exhibits significant activity against Gram-positive bacteria and demonstrates effectiveness in inhibiting tumor cell proliferation. This compound is utilized in cancer research and investigations aimed at understanding its therapeutic potential in oncological applications.

Lavendofuseomycin is a macrolide pentaene antibiotic that exerts its antibacterial activity by inhibiting protein synthesis in susceptible bacteria. This compound is valuable for research applications focused on antibacterial mechanisms and the development of novel antimicrobial agents. Its unique structure and mode of action make it a significant tool for investigating antibiotic resistance and exploring therapeutic options.

Paromamine is an antibiotic that targets ribosomal RNA (rRNA) components, inhibiting bacterial protein synthesis. This compound exhibits potent antibacterial activity, making it valuable for research into bacterial resistance mechanisms and antibiotic efficacy. Its role in elucidating the interactions between antibiotics and ribosomes contributes to the development of new therapeutic strategies against infectious diseases.

Temocillin is a semisynthetic β-lactam antibiotic that functions primarily through its inhibition of bacterial cell wall synthesis. This 6-alpha-methoxy penicillin derivative exhibits a broad spectrum of activity against most aerobic Gram-negative bacteria. It is particularly valuable in research settings focused on antibiotic resistance, bacterial pathogenesis, and the development of novel therapeutic strategies against Gram-negative infections.

Pirlimycin is a lincosamide antibiotic that targets Gram-positive bacteria. Its primary mechanism involves the inhibition of bacterial protein synthesis through binding to the 50S ribosomal subunit. This action disrupts the translation process, providing effective antimicrobial activity. Pirlimycin is commonly used in research to explore antibacterial mechanisms and resistance in bacterial infections.

Flurithromycin functions as a broad-spectrum antibiotic by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit. This compound exhibits significant antimicrobial activity against various gram-positive and some gram-negative bacteria. Flurithromycin is utilized in research applications focused on understanding bacterial infections and developing new therapeutic strategies.

Norfloxacin (nicotinate) is a fluoroquinolone antibiotic that targets bacterial DNA gyrase and topoisomerase IV, inhibiting their activity and preventing bacterial cell replication. This compound demonstrates significant antibacterial activity and has been utilized in veterinary medicine, particularly in animal husbandry and aquaculture. At elevated concentrations, norfloxacin nicotinate can also stimulate the innate immune response, making it a valuable tool for exploring immune modulation in research applications.

Cycloviracin B2 is an antibiotic with potent antiviral activity, primarily targeting herpes simplex virus type 1 (HSV-1). It exhibits strong inhibitory effects, making it a valuable tool for research into antiviral therapies and the mechanisms of viral infections. This compound is essential for studies focused on HSV-1 and other related viral pathogens.

Lysolipin I is a lipophilic antibiotic derived from Streptomyces violaceoniger, targeting bacterial cell membranes. It exhibits effective antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool for research in microbiology and antibiotic resistance studies. Its unique mechanism of action and broad-spectrum efficacy position it as a significant compound for exploring new therapeutic strategies against bacterial infections.

Loloatin B 10 is an antibiotic with significant antibacterial activity against gram-positive, antibiotic-resistant human pathogens. This compound targets bacterial cell viability and growth, making it a valuable tool for research applications focused on antibiotic resistance and developing new antimicrobial agents. Its efficacy against resistant strains highlights its potential in advancing therapeutic strategies in infectious disease management.

Aurein 2.3 is an antibiotic antimicrobial peptide targeting bacterial ATPases, primarily inhibiting E. coli ATPase activity. This compound demonstrates significant antibacterial activity, effectively suppressing cell growth in susceptible bacterial strains. Aurein 2.3 serves as a valuable tool in microbiological studies and the development of new antimicrobial therapies.

O-Deacetylravidomycin is an antibiotic derived from Streptomyces, functioning as a microbial metabolite. It demonstrates light-dependent antibacterial and anticancer properties, making it suitable for research applications in microbial resistance and cancer therapy studies.

Gramicidin B is a nonribosomal peptide antibiotic that exerts its action by forming ion-permeable channels in bacterial membranes. This mechanism disrupts osmotic balance, leading to cell death. Gramicidin B is widely used in research to study bacterial resistance, membrane dynamics, and the molecular mechanisms of antibiotic action. Its effectiveness against a range of Gram-positive bacteria makes it a valuable tool in microbiological investigations.

Faropenem is a potent beta-lactam antibiotic with oral bioavailability. It exhibits broad-spectrum antimicrobial activity against a variety of gram-positive and gram-negative bacteria, including both aerobes and anaerobes. Notably, Faropenem is resistant to hydrolysis by most beta-lactamases, including extended-spectrum and AmpC varieties. It has been developed as an oral proagent, faropenem medoxomil, for the investigation of respiratory tract infections and related conditions.

Respinomycin A2 is an anthracycline antibiotic known for its mechanism as an antitumor agent. It exhibits notable biological activity by inducing differentiation in leukemic K-562 cells, demonstrating potential in leukemia research and treatment. This compound may be utilized in studying the mechanisms of cancer differentiation and developing new therapeutic strategies against leukemia.

Althiomycin is a thiazole antibiotic derived from polyketide synthesis, primarily targeting Gram-positive bacteria. It exhibits potent antibacterial activity against strains such as Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes, with minimum inhibitory concentrations (MICs) of 25 μg/mL, 25 μg/mL, and 3.1 μg/mL, respectively. Additionally, Althiomycin inhibits protein synthesis in Escherichia coli at concentrations of 1 and 10 μg/mL, though it does not affect protein synthesis in isolated rabbit reticulocytes at 100 μg/mL. This compound is useful in antibiotic research and studies related to bacterial resistance mechanisms.

4-Methylaeruginoic acid is an antitumor antibiotic that selectively targets various human tumor cell lines. This compound demonstrates significant cytotoxic activity, making it a valuable agent for cancer research. It is utilized in studies investigating mechanisms of tumor cell inhibition and potential therapeutic applications in oncology.

Ritipenem acoxil is an oral-active beta-lactamase antibiotic designed to inhibit bacterial cell wall synthesis. It demonstrates significant activity against various bacterial strains, making it a valuable tool in the study of bacterial pneumonia. This compound serves as a critical reagent for researchers investigating antibiotic resistance and the mechanisms of bacterial infections.

Chartreusin sodium is an antibiotic targeting specific Gram-positive bacteria and mycobacteria. It exhibits inhibitory activity against pathogens, including Micrococcus flavus and Staphylococcus aureus phage. This compound is valuable for research focused on antibiotic resistance and the mechanisms of bacterial infection.

Helvecardin A is a glycopeptide antibiotic that targets and disrupts cell wall synthesis in bacteria. It demonstrates potent activity against both aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This compound serves as a valuable tool for research focused on antibiotic resistance and the mechanisms underlying Gram-positive bacterial infections.

Aurantiogliocladin is a weak antibiotic that primarily targets Staphylococcus epidermidis, exhibiting minimal activity against Staphylococcus aureus. This compound has shown the ability to inhibit biofilm formation, making it a valuable tool for studying bacterial adhesion and resistance mechanisms. Its selective properties may facilitate research into antibiotic efficacy and the development of strategies to combat biofilm-related infections.